Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study

Código QR

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study

Seigo Minami, Yoshitaka Ogata, Suguru Yamamoto, Kiyoshi Komuta Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan Background: Advanced non-small-cell lung cancer (NSCLC) eventually progresses after first-line chemotherapy, and usually requires salvage treatment. Although neither...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minami S, Ogata Y, Yamamoto S, Komuta K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ccf2f623dddc406dbf9492c85f8ea841
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami S, et al.
Publicado: (2016)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami S, et al.
Publicado: (2017)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami S, et al.
Publicado: (2017)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami S, et al.
Publicado: (2016)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Yawen Zheng, et al.
Publicado: (2021)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: Man He, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
por: Tadahiro Kuribayashi, et al.
Publicado: (2021)

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
por: Yokoi T, et al.
Publicado: (2012)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Non-small cell lung cancer: the era of targeted therapy
por: Antonoff MB, et al.
Publicado: (2012)

Epiregulin as a therapeutic target in non-small-cell lung cancer
por: Sunaga N, et al.
Publicado: (2015)

Emerging treatment options in the management of non-small cell lung cancer
por: Filosso PL, et al.
Publicado: (2011)

Non-small-cell lung carcinoma: role of the Notch signaling pathway
por: Barse L, et al.
Publicado: (2015)

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
por: Sugiura Y, et al.
Publicado: (2013)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi I, et al.
Publicado: (2014)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
por: Gou LY, Wu YL
Publicado: (2014)

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka M, et al.
Publicado: (2019)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Barbara Melosky, et al.
Publicado: (2021)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou N, et al.
Publicado: (2014)

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Guangbing Xiong, et al.
Publicado: (2021)

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
por: Takeda M, et al.
Publicado: (2011)

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
por: Karam SD, et al.
Publicado: (2013)

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis
por: Ke Gong MBBS, et al.
Publicado: (2021)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Nobukazu Fujimoto, et al.
Publicado: (2021)

Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis
por: Mo Tang PhD Student, et al.
Publicado: (2021)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Correction: Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations
Publicado: (2021)

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
por: Twelves C, et al.
Publicado: (2011)

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
por: Gabriela Palma, et al.
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)